Dihydromyricetin (Dhm) for Anti-Inflammatory

Research suggests that dihydromyricetin (DHM) demonstrates broad anti-inflammatory activity across a wide range of biological contexts, with studies pointing to its ability to suppress key inflammatory signaling pathways — particularly NF-κB, NLRP3, and TLR4 — while also supporting antioxidant defenses through mechanisms such as Nrf2 activation. The available evidence comes entirely from preclinical sources, including in vitro cell culture experiments, animal models of conditions such as asthma, stroke, COPD, kidney injury, liver disease, and neuroinflammation, along with several narrative reviews synthesizing this preclinical literature; no randomized controlled trials or human clinical studies were included among the reviewed studies, and the overall direction of findings is consistently supportive. Studies indicate that DHM's anti-inflammatory effects appear to operate through multiple molecular mechanisms simultaneously, including reduction of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β, modulation of oxidative stress, and regulation of cellular processes such as autophagy and pyroptosis, suggesting it may have relevance across a variety of inflammation-driven conditions. However, because all current evidence is derived from laboratory and animal models, it remains unknown whether these effects translate meaningfully to humans, and the gap between preclinical promise and clinically validated outcomes represents a significant and openly acknowledged limitation across the research reviewed.